Trial Information
Study of Predictive Proteomic Factors of the Response to Exclusive Concomitant Radiochemotherapy in Oesophageal Cancer
Further informations will be provided by Centre Oscar Lambret.
Inclusion Criteria:
- Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a),
histologically proven
- Treated by exclusive concomitant radiochemotherapy
- Written informed consent
Exclusion Criteria:
- Presence of a second uncontrolled cancer
- Metastatic carcinoma
- Metastatic disease, except cervical lymphnodes... (M1a)
- In situ carcinoma
- Eso-gastric junction cancer (Siewert II ou III)
- Inclusion in a clinical trial with an experimental drug during the study and until 15
weeks after the end of radiotherapy)
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Proteomic analysis by Protein-Chip Technology of Ciphergen and mass spectrometry
Outcome Time Frame:
15 weeks after the end of irradiation
Safety Issue:
No
Principal Investigator
ADENIS Antoine, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Centre Oscar Lambret
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
2006-13
NCT ID:
NCT00911092
Start Date:
October 2007
Completion Date:
December 2011
Related Keywords:
- Esophageal Cancer
- Oesophageal cancer
- exclusive concomitant radiochemotherapy
- Esophageal Diseases
- Esophageal Neoplasms